| Name | Title | Contact Details |
|---|
Greens At Greenwich is a Greenwich, CT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
CCS Cell Culture Service is a San Francisco, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Vital Incite: Population Health Solutions, is a health care consulting firm offering the insight needed to strategically align healthcare resources to meet the needs of employee populations. Data is the driving force behind the Vital Incite Population Health Solution. We use it to: • Identify health risks trends within an employee population. • Understand how employees are accessing healthcare. • Evaluate the effectiveness of health benefit and wellness programs. • Hold ourselves and vendor partners accountable to improve health risks and expenses Our analytics tools turn health care data into actionable intelligence so that employers can make informed decisions about the health and wellness programs they offer to employees. Our analytics tools combine multiple data sources, including: • Claims Data (medical, dental, vision) • Health Risk Assessments • Biometric Data • Vendor Data We use what we learn from the data to develop program objectives, set impact expectations and track the effectiveness of the program. We are focused on the big picture, helping employers manage their health care spend and helping employees improve their health. We don`t try to solve employer problems with our own solutions. We identify which resources are required, assist an employer in choosing the provider of those resources and then continue to monitor the impact of those programs.
CommunityHealth is a Chicago, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Dimension Therapeutics, Inc. is a rare disease company focused on discovering and developing new therapeutic products for people living with devastating rare diseases associated with the liver and based on the most advanced adeno-associated virus (AAV) delivery technology. The company is advancing multiple programs toward clinical development, including: programs addressing unmet needs for patients suffering from OTC deficiency and GSDIa; a collaboration with Bayer HealthCare in hemophilia A, and a wholly owned program in hemophilia B, which is expected to enter clinical testing in the second half of 2015. Dimension has preferred access to multiple AAV vectors from REGENXBIO. The Dimension team and senior advisors include biotech industry veterans and renowned thought leaders in gene therapy and rare diseases.